双成药业：董事会关于本次交易相关主体不存在《上市公司监管指引第7号——上市公司重大资产重组相关股票异常交易监管》第十二条以及《深圳证券交易所上市公司自律监管指引第8号——重大资产重组》第三十条规定的不得参与任何上市公司重大资产重组情形的说明

Shuangcheng Pharmaceutical: Explanation of the board of directors that there are no entities involved in this transaction that are prohibited from participating in the material assets restructuring situation of any listed company as stipulated in Article 12 of the “Supervisory Guidelines for Listed Companies No. 7 - Supervision of Abnormal Stock Transactions Related to Major Asset Restructurings of Listed Companies” and Article 30 of the “Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 8 - Major Asset Restructurings”